May 8th, 1:30 PM - 3:00 PM

A Case of Mistaken Identity: Biomarkers for High Risk Premalignant Breast Lesions

D. Joseph Jerry  
*University of Massachusetts - Amherst*

Karl Simin  
*University of Massachusetts Medical School*

Follow this and additional works at: [https://escholarship.umassmed.edu/cts_retreat](https://escholarship.umassmed.edu/cts_retreat)

Part of the Biological Factors Commons, Cancer Biology Commons, Diagnosis Commons, Neoplasms Commons, Pathological Conditions, Signs and Symptoms Commons, and the Translational Medical Research Commons

This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License.

[https://escholarship.umassmed.edu/cts_retreat/2013/presentations/16](https://escholarship.umassmed.edu/cts_retreat/2013/presentations/16)

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in UMass Center for Clinical and Translational Science Research Retreat by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
A case of mistaken identity --- Biomarkers for high risk premalignant breast lesions

D. Joseph Jerry, UMass Amherst and PVLSI
Karl Simin, UMass Medical
May 8th, 2013
Estimated costs: $20,000 to $100,000/patient.

Campbell JD, Ramsey SD. Pharmacoeconomics. 2009;27(3):199-209. PMID: 19354340
Atypical hyperplasias
Progression to invasive cancer

50,000 new cases annually
Expect 10,000 new cases annually
Up to $1B to treat
Developing biomarkers of high risk premalignant breast lesions

Subtypes of Atypical Hyperplasias

Subtypes of lesions with malignant potential
Bioanalyzer electropherograms

Intact RNA

FFPE RNA
Patient Population:
Diagnosis of Breast Cancer or Benign Breast Disease

IRB-approved Registry
Patient consent
Assign study ID

Patient Registry
Survey data
Clinical data
Archived tissues

Data Manager
• Collate data
• Provides summary data
• Extract data from clinical records
• Coded data for IRB-approved projects

Data/Tissue With Study ID

Project 1
Project 2
Project 3
Project 4
Atypical hyperplasia (UMMS 1999-2003)

Upstaging upon re-excision

2833 breast core biopsies
120 with primary diagnosis of ADH
Summary

• Value of diagnostic test
  – Large interobserver variability in diagnosing premalignant lesions (Jain et al., 2011. PMID 21532546)
  – Identify subgroups to benefit from preventive therapies.
  – Identify molecular pathways to provide appropriate preventive treatments

• Technical challenges
  – Minute amounts of tissue
  – Fragmentation of RNA in FFPE tissues
  – Amplification and labeling for robust detection
University of Massachusetts - Amherst
D. Joseph Jerry, Ph.D.
Ellen Dickinson
Amy Roberts
Jeff Kane
Mary Hagen

UMass Medical Center
Karl Simin, Ph.D.
Ashraf Khan, M.D.

PVLSI
Sallie Smith Schneider, Ph.D.
Kelly Gauger

Baystate Medical Center
Grace Makari-Judson, M.D.
Giovanna Crisi, M.D.

Funding from
NIH, NIEHS, Avon Foundation
Rays of Hope Foundation,
Life Science Moment Fund